A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder

Phase 3 Completed 7 enrolled Massachusetts General Hospital

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is an 8-week pilot trial with oxytocin nasal spray (Syntocinon) as a treatment for social impairment in children and adults with high functioning autism spectrum disorders (ASD). The investigators hypothesize that oxytocin will be safe, tolerable, and effective in improving social deficits in individuals with ASD.

Timeline

Start: 2017-10-09
Primary completion: 2019-01-09
Completion: 2019-01-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oxytocin	Peptide	48 iu	Intranasal

A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder

Summary

Timeline

Drugs

Indications